, Volume 32, Issue 2, pp 179–179 | Cite as

Authors’ Reply to Dr. Riccardo Perfetti: “LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes”

  • Yvette N. Lamb
  • Yahiya Y. Syed
Letter to the Editor

We thank Dr. Perfetti [1] for his letter to the editor. We appreciate his concern that readers may be unclear as to which insulin glargine formulation is the reference product and we wish to confirm that the reference insulin glargine in the studies reviewed is indeed insulin glargine 100 U/mL (Lantus® [2, 3]). We will clarify this point in our article by specifying in the abstract and in the introduction that subcutaneous once-daily LY2963016 insulin glargine 100 U/mL (Abasaglar®/Basaglar® [4, 5]) has been approved as a biosimilar in the EU and as a follow-on biologic in the USA to reference insulin glargine 100 U/mL (Lantus®).


Compliance with ethical standards


No external funding was used to assist in the preparation of this letter.

Conflict of interest

Yvette Lamb and Yahiya Syed are salaried employees of Adis/Springer and declare no relevant conflicts of interest.


  1. 1.
    Perfetti R. Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes. BioDrugs. 2018. Scholar
  2. 2.
    Sanofi. US prescribing information for Lantus® (insulin glargine injection) solution, for subcutaneous injection. 2015. Accessed 16 Feb 2018.
  3. 3.
    European Medicines Agency. Lantus: summary of product characteristics. 2017. Accessed 16 Feb 2018.
  4. 4.
    European Medicines Agency. Abasaglar (previously Abasria): summary of product characteristics. 2016. Accessed 16 Feb 2018.
  5. 5.
    Eli Lilly and Company. US prescribing information for Basaglar (insulin glargine injection), for subcutaneous use. 2016. Accessed 16 Feb 2018.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations